中科院《国际期刊预警名单（试行）》名单
2023年01月发布的2023版：不在预警名单中
2021年12月发布的2021版：不在预警名单中
2021年01月发布的2020版：不在预警名单中
《国际期刊预警名单（试行）》2023版共计包含28本期刊（查看）
《国际期刊预警名单（试行）》2021版共计包含35本期刊（查看）
《国际期刊预警名单（试行）》2020版共计包含65本期刊（查看）
《Therapeutic Advances in Medical Oncology》相关链接
PubMed Central (PMC)链接：
http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1758-8359%5BISSN%5D
平均审稿速度：
15 Weeks
平均录用比例：
123学术网预审服务：
经过123学术网预审的论文，能够提前知晓自己的论文稿件是否达到自己目标分区、分值的杂志社的录用标准，同时节约自己大量投稿时间，若预审通过，123学术网客服会进一步向您反馈预审结果，如果双方对预审结果达成一致，则需要与我方签订咨询服务协议，以协助您结合审稿人的审稿意见进一步优化稿件质量，以实现文章录用结果。
若预审不能通过，说明论文稿件质量无法达到杂志社的录用标准，可考虑123学术网润色服务，不仅能满足Therapeutic Advances in Medical Oncology的语言要求，还能让Therapeutic Advances in Medical Oncology编辑和审稿人得到更好的审稿体验，让稿件最大限度被Therapeutic Advances in Medical Oncology编辑和审稿人充分理解和公正评估。
123学术网已助力全球10万+作者顺利发表论文。
《Therapeutic Advances in Medical Oncology》期刊简介
Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.
The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.
Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). Therapeutic Advances in Medical Oncology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The journal adheres to a blind review process in which the reviewer’s name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; and Online First publication is usually within 3 weeks of Acceptance.
